Title:

Director, Division of Maternal Fetal Medicine, New York-Presbyterian Hospital

Attending OB/GYN, New York-Presbyterian Hospital

Education:
Jefferson Medical College, Cum Laude, MD (1972)

Internship:
Thomas Jefferson University Hospital (1972-1973)

Residency:
Thomas Jefferson University Hospital, Department of Obstetrics and Gynecology (1973-1976) and Chief Resident (1975-1976)

Fellowship:
Thomas Jefferson University Hospital, Maternal Fetal Medicine (1976-1978)
Thomas Jefferson University Hospital, Medical Genetics (1990-1991)

Board Certification:
American Board of Obstetrics and Gynecology (1978)
Subspecialty Board, Maternal Fetal Medicine (1981)
- Voluntarily Recertified, ABOG - 1999
American Board of Medical Genetics (1993) - Recertified in 2003

Before joining Columbia as the Director of Maternal Fetal Medicine, Dr. Wapner was at Drexel University College of Medicine as a Professor of Obstetrics and Gynecology. Prior to Drexel, he was at Thomas Jefferson University for 22 years where he was also the Director of Maternal Fetal Medicine.

Dr. Wapner is a nationally known clinician specializing in first trimester screening and invasive procedures, such as CVS, PUBS and amniocentesis. He was instrumental in developing CVS and multi-fetal reduction procedures. He has also authored or co-authored over 120 publications. He has been an active investigator in the area of Maternal-Fetal Medicine throughout his career and has been, or is, either a principal or co-investigator for a number of multi-center studies including much of the original work on chorionic villus sampling and multi-fetal pregnancy reductions. He served as the PI for the Philadelphia Center in the Maternal Fetal Medicine Units Network for the past eight years and will continue that work at Columbia. He also served as Co-PI of the NICHD sponsored NIFTY trial investigating the retrieval of fetal cells from the maternal circulation. He is Co-PI of the EATA trial in which 13 centers in the US and Europe performed a randomized comparison of amniocentesis and CVS in weeks 13 and 14 of gestation. This study also evaluated the efficacy of first trimester screening for fetal aneuploidy in a multicentered fashion for which Dr. Wapner served as PI. He has had a significant role in the development of multidisciplinary research studies and clinical research centers throughout his career. Dr. Wapner continues to practice clinical Maternal- Fetal Medicine and has approximately 25% of his time protected for research activities.